Combining targeted therapy with a stroma-modulating agent for pancreatic cancer
Combination of tumor targeted therapy with stroma modulating agent for PDAC
This study is exploring a new way to treat pancreatic cancer by using a special combination of drugs that not only attack the cancer cells but also help the surrounding tissue, making it easier for the medicine to work better, and patients may have the chance to participate in testing how safe and effective this treatment is.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. John's University NIH-funded |
| Lab location | 1 site (Queens, United States) |
| Project ID | NIH-11083663 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer. The study aims to enhance the effectiveness of anticancer drugs by targeting both the tumor cells and the surrounding stroma, which often hinders drug delivery. By using a specific inhibitor to modify the tumor microenvironment and a novel class of anticancer molecules called PROTACs, the research seeks to improve drug uptake and overcome resistance to existing therapies. Patients may be involved in trials assessing the safety and efficacy of these combined treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who have not responded well to standard treatments.
Not a fit: Patients with other types of cancer or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: While the approach of targeting both tumor cells and the stroma is innovative, preliminary studies have shown promise in similar strategies, indicating potential for success.
Where this research is happening
Queens, United States
- St. John's University — Queens, United States (Active)
Researchers
- Principal investigator: Patel, Ketankumar D. — St. John's University
- Study coordinator: Patel, Ketankumar D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.